[18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription

• Published in: Seminars in radiation oncology Vol. 33; no. 3; pp. 287 - 297
• Main Authors: Kaanders, Johannes H.A.M., Bussink, Johan, Aarntzen, Erik H.J.G., Braam, Pètra, Rütten, Heidi, van der Maazen, Richard W.M., Verheij, Marcel, van den Bosch, Sven
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2023
• Subjects: Fluorodeoxyglucose F18; Glucose; Humans; Neoplasms - diagnostic imaging; Neoplasms - radiotherapy; Positron-Emission Tomography - methods; Radiopharmaceuticals
• ISSN: 1053-4296; 1532-9461
• DOI: 10.1016/j.semradonc.2023.03.006

PET imaging with 2’-deoxy-2’-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.